pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·24m ago·1 min read
save

OrbiMed raises $3B in new life sciences funds, including $1B+ for Asia

OrbiMed, one of the biggest life science investors in the world, has raised $3 billion across two new funds. OrbiMed’s 10th private equity fund in its flagship series put together “over $1.9 billion” to invest ...

Oct 15, 2026·read at Endpoints ↗

October 15, 2026 09:55 AM EDT Financing Or­biMed rais­es $3B in new life sci­ences funds, in­clud­ing $1B+ for Asia Max Gelman Senior Editor Or­biMed, one of the biggest life sci­ence in­vestors in the world, has raised $3 bil­lion across two new funds. Or­biMed’s 10th pri­vate eq­ui­ty fund in … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
83 words · retrieved 7m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

no entities indexed yet

related stories

  • 1h agoAI will force doctors to focus on clinical reasoning, experts sayEndpoints
  • 3h agoVanda’s social anxiety drug flunks Phase 3 trial in female patientsEndpoints
  • 3h agoPaul Stoffels to bring Galapagos’ cell therapies back to lifeEndpoints
  • 6h agoIambic snags $150M IPO for AI-driven cancer pipelineEndpoints
  • 8h agoOMass Therapeutics collects $310M to chase Neurocrine, Vertex in genetic adrenal disorderEndpoints